Vortex Energy Announces Plans for Ground Gravity Survey at the Robinsons River Salt Project
Next Phase of Geophysical Work Advances Priority Targets Following August Technical StudyVANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce plans to undertake a targeted ground gravity survey at its 100%-owned Robinsons River Salt Project (the “Project”), located approximately 35 kilometres south of Stephenville, Newfoundland and Labrador. The survey has been selected as the Co
YahooyesterdayVRTX
The Market May Be Telling Us We're Entering A Capital Formation Cycle
My clustering stock screener is giving us a much more interesting macro signal than simply energy stocks are strong. The portfolio is not simply long commodities. It's long capital intensity
SeekingAlphayesterdayVRTX
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
We'll know a little more about the company's prospects by the end of the year.
YahooyesterdayVRTX
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo2 days agoVRTX
How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?
Vertex Pharmaceuticals has underperformed the Biotech industry over the past year, but analysts are moderately optimistic about the stock’s prospects.
Yahoo2 days agoVRTX
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target
Morgan Stanley analyst Terence Flynn reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.
Benzinga2 days agoVRTX
Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks
Vertex Pharmaceuticals stock has delivered strong multi year gains, and current valuation checks suggest the shares now look closer to fairly priced than clearly cheap or clearly expensive. Vertex Pharmaceuticals has returned 184.9% over the past 5 years, which puts extra focus on whether the current price still offers an appealing entry point for new money. Expectations for continued revenue and cash flow growth from its existing treatment portfolio can support today’s valuation, while any...
Yahoo2 days agoVRTX
Vertex Pharmaceuticals (VRTX) Could Be 3% Undervalued If Its Pipeline Growth Holds
How Vertex Pharmaceuticals Stock Has Been Trading Recently Vertex Pharmaceuticals (VRTX) has drawn fresh investor attention as its share price reached $544.52 at the last close on 1 September 2026. Recent returns show mixed short term moves, with stronger performance over the past 3 months and over the past year. Over the past year, Vertex Pharmaceuticals has combined a strong 90 day share price return of 28.10% with a 1 year total shareholder return of 39.26%. This suggests that recent price...
Yahoo3 days agoVRTX
Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform
The completed acquisition adds PALSONIFY and atumelnant to Vertex’s portfolio, with the two therapies carrying combined peak annual revenue potential of more than $5 billion according to the company. Key Investor TakeawaysVertex Pharmaceuticals (NASDAQ:VRTX) completed its approximately $10 billion equity-value acquisition of Crinetics Pharmaceuticals on September 1, 2026.
Yahoo3 days agoVRTX
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
BOSTON, September 01, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases. Vertex also announced the expansion of its executive leadership team, in support of the Company’s continued growth and diversification.
Yahoo3 days agoVRTX
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General Counsel.
Yahoo3 days agoVRTX
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
Yahoo4 days agoVRTX
Vertex to Participate in Upcoming September Investor Conferences
BOSTON, August 26, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences.
Yahoo9 days agoVRTX
Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock
Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.
Yahoo9 days agoVRTX
2 Large-Cap Stocks to Research Further and 1 We Question
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Yahoo9 days agoVRTX
Inflation Is Rising Again. History Says These 2 Stocks Are Among the Smartest Places to Hide
Inflation affects corporations differently. These two have the tools to navigate the challenge better than most.
Yahoo11 days agoVRTX
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
Don't bet against Vertex Pharmaceuticals in cystic fibrosis.
Yahoo15 days agoVRTX
Are Wall Street Analysts Bullish on Vertex Stock?
Vertex Pharmaceuticals has raced ahead of the market, while analysts continue to give the stock a decidedly optimistic outlook.
Yahoo15 days agoVRTX
Vortex Energy Announces Final Ambient Noise Tomography Results for the Robinsons River Salt Project
ANT survey delivers a 3D subsurface view that reinforces the Robinsons River geological model and de-risks the next stage of technical workVANCOUVER, British Columbia, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce the final results of the Ambient Noise Tomography (“ANT”) survey completed at the Company's 100%-owned Robinsons River Salt Project (the “Project”), located approximately 35 kilometres south
Yahoo17 days agoVRTX
3 Cash-Producing Stocks on Our Watchlist
Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.
Yahoo17 days agoVRTX
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?
On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, […]
Yahoo20 days agoVRTX
Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?
Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than as an obvious bargain. Recent news around pipeline catalysts and competitive threats keeps the focus on whether that pricing still leaves enough room for missteps. Over the past 5 years, Vertex Pharmaceuticals has returned 158.2%, which puts recent valuation questions in the context of a stock that has already rewarded long...
Yahoo20 days agoVRTX
$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.35% on an annualized basis producing an average annual return of 14.69%. Currently, Vertex Pharmaceuticals has a market
Benzinga21 days agoVRTX
Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)
Vertex Pharmaceuticals' revenue from its cystic fibrosis franchise grew 10% quarter-on-quarter. Click here to see why VRTX stock is a Buy.
SeekingAlpha21 days agoVRTX
Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public
A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science and the filings actually show.
Yahoo22 days agoVRTX
Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says
Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provid
Yahoo23 days agoVRTX
One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses
Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial failure, while Vertex Pharmaceuticals (NASDAQ:VRTX), the company whose drug dominance Sionna was attempting to challenge, surged to new highs. The Pipeline Flop Sionna […]
Yahoo23 days agoVRTX
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call
Vertex Pharmaceuticals’ second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfolio and accelerating uptake of newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani attributed revenue growth to “the strength of our cystic fibrosis portfolio and the growing contributions from our newer products,” while also emphasizing progress in regulatory and clinical milestones. Management specifically noted that ALYFTREK a
Yahoo23 days agoVRTX
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.
Yahoo24 days agoVRTX
Vertex (VRTX) Q2 2026 Earnings Call Transcript
Revenue hit $3.3 billion with guidance raised on strong newer product growth.
Yahoo24 days agoVRTX